GoodRx Holdings, Inc. (GDRX) intrinsic value & 10-year financials
GoodRx Holdings, Inc. (GDRX) has a Graham intrinsic value of $1.59 per share. At $3.36 on Oct 17, 2026, the stock trades 111% above that value. Over the last 9 fiscal years revenue grew 18.0% a year to $796.9M, with an average return on invested capital of -181.4%.
- Graham intrinsic value
- $1.59
- Share price (Oct 17, 2026)
- $3.36
- Price vs Graham value
- 111% above
- Market cap
- $1.2B
- Revenue (FY2025)
- $796.9M
- Revenue growth (9-yr CAGR)
- 18.0%
- ROIC (10-yr avg)
- -181.4%
- Free cash flow (FY2025)
- $164.4M
GDRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $796.9M | $30.4M | $0.09 | $164.4M | 11.0% | 5.5% |
| FY2024 | $792.3M | $16.4M | $0.04 | $182.7M | 8.3% | 4.3% |
| FY2023 | $750.3M | -$8.9M | -$0.02 | $137.2M | -3.6% | -1.7% |
| FY2022 | $766.6M | -$32.8M | -$0.08 | $142.8M | 0.2% | 0.3% |
| FY2021 | $745.4M | -$25.3M | -$0.06 | $174.2M | 1.8% | 2.6% |
| FY2020 | $550.7M | -$293.6M | -$1.07 | $110.8M | -50.1% | -1424.0% |
| FY2019 | $388.2M | $66.0M | $0.18 | $81.9M | 36.0% | -27.4% |
| FY2018 | $249.5M | $43.8M | $0.06 | $44.4M | 31.0% | -10.8% |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
GoodRx Holdings, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
GoodRx Holdings, Inc. has historically struggled to out-earn its cost of capital, averaging just -5.2% ROIC.
GoodRx Holdings, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, GoodRx Holdings, Inc. is modeled at 6.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $1.59 per share.